Scott Powell, Executive Vice President of Volition, will provide an update on Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced product launch of its Nu.QTM Colorectal Cancer Screening Triage Test.
VolitionRx to present at 2nd Annual Disruptive Growth & Healthcare Conference
VolitionRx Limited will present at Source Capital Group's 2nd Annual Disruptive Growth & Healthcare Conference being held on February 15-16 in New York
Quick facts: VolitionRx
Price: 4.48 USD
Market Cap: $184.09 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE